Allogene Therapeutics, Inc.
Public company- Headquarters
- SOUTH SAN FRANCISCO, California
- Industry
- Biotechnology
- Ticker
- ALLO
- CIK
- 0001737287
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| CFOGeoffrey Parker | Sep 2, 2026 | Departed |
Related companies
Same industry and state, with recent events.
- Vir Biotechnology, Inc.
Class III director appointed: Suzanne Topalian, M.D.
- AMGEN INC
director appointed: David W. Gibbs
- Cardiff Oncology, Inc.
CMO appointed: Leila Alland
- Vaxart, Inc.
member of the Board appointed: Raquel C. Bono, M.D., M.B.A., FACS
- Executive departure
CFO departs: Geoffrey Parker
Geoffrey Parker, Executive Vice President and Chief Financial Officer and principal financial officer of Allogene Therapeutics, Inc., retires the role, effective November 6, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Sep 2, 2026Role: Executive Vice President and Chief Financial Officer and principal financial officer
Only one public record so far. We add events as soon as a new filing lands; watch Allogene Therapeutics, Inc. to get them in your digest.
Last verified Nov 8, 2026